Developing effective CAR T-cell therapies begins with selecting the optimal chimeric antigen receptor (CAR). Rapid and comprehensive screening of CAR candidates enables researchers to identify high-performing molecules that can improve therapeutic outcomes and accelerate development timelines.
In this webinar, you'll discover how CAR FINDER streamlines CAR screening, helping researchers efficiently identify the most promising CAR candidates for next-generation cell therapies.
Dr. Sandy Tretbar
Group Leader, Cell and Molecular Biology Unit, Fraunhofer IZI
Dr. Sandy Tretbar is a Molecular Biology and RNA Biochemist by training who spent her PhD and postdoc time in Germany and the US. After her second Postdoc in the immunology field, she joined the Fraunhofer IZI in 2018 as Research Associate and advanced as Group Leader in 2021. Now, she combines her long-standing RNA research experience with cell therapy development in immune oncology to investigate mRNA-based cell and gene therapies for the treatment of cancer and various other diseases.